About: TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
Sector: Healthcare
Industry: Biotechnology
Latest price: $61.63 (+1.45%)
TGTX NASDAQ TG Therapeutics Inc
TG Therapeutics Inc share price
TGTX price activity
Last Price
$61.630
Change (24hr)
0.88 USD (1.45%)
Volume
1.87M
Volume (4w avg)
-
Open
$61.85
Day Range
$60.31 - $62.78
Previous Close
$60.75
Last Trade
04 Nov, 9:00 pm GMT+0
Delayed
04 Nov, 9:00 pm GMT+0
TGTX price performance
Delayed
04 Nov, 9:00 pm GMT+0
TGTX details
TGTX Market Signals